Labcorp Lays Out AI and Specialty Testing Growth Plan Through 2029
Labcorp laid out a growth strategy and long-term financial outlook at its 2026 Investor Day, emphasizing innovation, technological advances, and deploying scientific insights to guide therapy development. For 2026, it targets sales of $14.710 billion to $14.827 billion and, through 2029, expects 5% to 8% compound annual revenue growth and 8.5% to 11.5% compound annual adjusted EPS growth.